简体中文
English
Website review
This review may include AI-generated content and is not individually verified. Domain, certificate and other facts come from the observed data on this page.
What is Johnson & Johnson?
Johnson & Johnson is a global healthcare company organized around two broad businesses described on its site: Innovative Medicine, which develops medicines and therapies, and MedTech, which makes medical devices and surgical technologies. The company frames its work around complex diseases—prevention, treatment and more personalized care—rather than a single product line.
What the two sides cover
| Business | Stated focus areas | What that means in practice |
|---|---|---|
| Innovative Medicine | Oncology, Immunology, Neuroscience, Cardiopulmonary | Prescription medicines and therapies for serious or chronic conditions |
| MedTech | Cardiovascular, Orthopaedics, Surgery, Vision | Devices and technology for surgical and clinical care, including less invasive approaches |
The site also highlights specific programs: CAR-T cell therapy manufacturing for multiple myeloma, targeted oral peptides, and the OTTAVA robotic surgical system. These illustrate the range—from cell therapy supply chains to surgical robotics.
Who it matters to
- Patients and caregivers looking for background on treatment areas and how certain therapies are made.
- Clinicians and researchers interested in the company's stated areas of innovation.
- Job seekers, since the site maintains a careers section with openings and hiring programs.
- Investors and journalists, who can follow earnings updates and company news.
As a next step, decide which audience you are: if you want treatment-area detail, start with the Innovative Medicine or MedTech sections; if you are evaluating the company as an employer, go to the careers pages. For independent context on the company, Reuters and SEC filings are useful complements to a corporate site.
How does Johnson & Johnson's Innovative Medicine division differ from its MedTech business?
Johnson & Johnson's Innovative Medicine division develops medicines and therapies, while MedTech develops devices and surgical technologies. The site frames the first around treating disease through science-based pharmaceuticals and the second around precision treatment, restoring anatomy and less invasive healing.
Where the two businesses focus
| Innovative Medicine | MedTech | |
|---|---|---|
| What it makes | Medicines and therapies | Medical devices and technology |
| Stated areas | Oncology, Immunology, Neuroscience, Cardiopulmonary | Cardiovascular, Orthopaedics, Surgery, Vision |
| Stated approach | Science-based innovation informed by patients | Biology and technology combined, with pinpoint precision in hard-to-reach parts of the body |
The practical difference is what a patient experiences. Someone with multiple myeloma may encounter Innovative Medicine through a therapy such as CAR-T cell treatment, which the site describes as transforming a patient's own cells into a targeted treatment. Someone with a damaged joint or a heart condition is more likely to encounter MedTech through a device or surgical procedure.
The site's examples also show different kinds of complexity. Innovative Medicine work includes targeted oral peptides, aimed at delivering peptide therapies by mouth and hitting their target more precisely. MedTech work includes the OTTAVA robotic surgical system. One is about what goes into the body as a drug; the other is about how a procedure is performed.
How to use this distinction
If you are researching a condition, start with the division that matches the type of care: medicines for diseases such as cancer, immune conditions or neurological disorders; devices and surgery for cardiovascular, orthopaedic, surgical or vision needs. For company or career research, treat them as separate businesses with different science, supply chains and skills.
For broader context, the parent company's official site is Johnson & Johnson.
What is CAR-T cell therapy and how does Johnson & Johnson manufacture and deliver it for multiple myeloma?
CAR-T cell therapy is a personalized cancer treatment in which a patient's own T cells are genetically engineered to recognize and attack cancer cells. For multiple myeloma, Johnson & Johnson describes a complex, carefully controlled process of turning those cells into a targeted therapy and then delivering it back to patients. Jessica Torfs, director of Global CAR-T Supply Chain at Johnson & Johnson, explains in the company's behind-the-scenes piece that this is a nuanced, multi-step operation.
What the page tells us
- Johnson & Johnson's Innovative Medicine business focuses on oncology, immunology, neuroscience and cardiopulmonary, with science "informed and inspired" by patients.
- Its CAR-T work for multiple myeloma is presented as a personalized therapy, meaning the starting material is the patient's own cells rather than an off-the-shelf product.
- The manufacturing and delivery process is described as complex, involving global supply-chain coordination from cell collection through to treatment.
A practical way to think about it
For a patient or caregiver, the key implication is that CAR-T is not a single appointment. It typically involves collecting a patient's cells, engineering and expanding them in a specialized facility, and returning them for infusion—each step with its own timing and logistics. That is why supply-chain roles like the one Torfs holds matter: delays or coordination failures at any stage affect when a patient can be treated.
For clinicians and researchers, the page signals where Johnson & Johnson is concentrating effort: precision, personalization and manufacturing reliability in cell therapy. The company also highlights related work on targeted oral peptides and its OTTAVA robotic surgical system, which shows a broader push toward less invasive, more individualized treatment.
Next step
If you are evaluating CAR-T for multiple myeloma, ask your care team about the specific product, the collection-to-infusion timeline, and what happens if manufacturing or scheduling slips. For company context, see Johnson & Johnson.
How do targeted oral peptides work, and why are they significant for treating conditions like plaque psoriasis?
Targeted oral peptides are small protein-like molecules designed to be swallowed rather than injected, engineered to bind a specific biological target more precisely and to survive the digestive system well enough to reach it. Their significance for plaque psoriasis is convenience and earlier, more tolerable treatment: a pill that acts on a defined immune pathway could offer an alternative to injectable biologics for moderate-to-severe disease, though it still has to prove comparable durability and safety.
What the page says, and what it doesn't
Johnson & Johnson's site frames this in its own words: it describes targeted oral peptides as "a new type of medication … tackling a problem that has long frustrated drug developers: how to deliver peptide therapies orally and hit their target more precisely." It also notes that ICOTYDE® (icotrokinra), described as "the first-of-its-kind targeted oral peptide therapy for moderate to severe plaque psoriasis," was named to Time's Best Inventions of 2026 list. That is the company's framing of its own pipeline, not independent clinical evidence. The page does not give dosing, trial results, or comparison data against existing therapies, so those questions belong with prescribing information and published trials, not the homepage.
Why the oral route matters for psoriasis
Plaque psoriasis is chronic, so treatment is long-term and adherence matters as much as potency. A daily pill removes cold-chain handling, injection training and clinic visits that make injectables harder to sustain for some patients. Precision targeting matters too: the aim is to dampen the specific inflammatory signaling driving plaques while leaving broader immune defenses less disturbed, which is the trade-off any psoriasis therapy faces.
Decision criteria for a reader
- Severity and prior treatment: oral options are most relevant for people who need systemic therapy but want to avoid or delay injectables.
- Monitoring burden: oral small molecules and peptides typically require periodic labs; ask what monitoring applies.
- Evidence stage: distinguish a regulatory approval from a pipeline candidate and a press recognition.
- Long-term data: psoriasis treatment is measured in years, so durability and safety follow-up are the deciding factors.
For background on the condition and treatment classes, the National Psoriasis Foundation and American Academy of Dermatology publish patient-oriented comparisons; confirm any product's status through the FDA.
What is Johnson & Johnson's OTTAVA Robotic Surgical System and how does it change surgical procedures?
Johnson & Johnson's OTTAVA Robotic Surgical System is a robotic-assisted surgery platform from its MedTech business. The site presents it as part of a broader push toward "smarter, less invasive, more personalized" treatment, and links to an inside look at how the system was developed. That framing places OTTAVA alongside the company's stated focus on precision in hard-to-reach areas of the body, rather than as a standalone gadget.
What the site actually says — and what it doesn't
The site names OTTAVA and points to a development story, but the excerpt provided does not describe its mechanism, its specific clinical uses, or how it compares with existing robotic surgery systems. So the honest answer to "how does it change surgical procedures" is: the site positions it as part of a shift toward less invasive, more precise intervention, but the detail needed to explain the change concretely sits in the linked development article, not in the summary text.
Who should look closer
- Patients or caregivers researching robotic-assisted options for a planned procedure: treat the site as a starting point, then ask the surgeon whether a robotic approach is appropriate for that specific operation and what the evidence is for that use.
- Clinicians and hospital procurement teams evaluating platforms: the development article is more useful than the marketing summary, since it may touch on design decisions and engineering trade-offs.
- Students or analysts tracking surgical robotics: the site is useful for the company's own positioning, less so for independent comparative data.
A practical next step
If you want to understand the system rather than the branding, read the OTTAVA development piece linked from the site, and pair it with independent sources on robotic-assisted surgery generally. For context on the company's wider portfolio, Johnson & Johnson covers its Innovative Medicine and MedTech areas, including Surgery and Vision.
What career opportunities and hiring programs does Johnson & Johnson offer?
Johnson & Johnson presents careers across two broad business areas—Innovative Medicine (oncology, immunology, neuroscience, cardiopulmonary) and MedTech (cardiovascular, orthopaedics, surgery, vision)—and its careers section points visitors to current job openings and to hiring programs. The site does not list specific roles or program names in the supplied page content, so treat the categories below as the general shape of what such a large healthcare company hires for, and check the live careers pages for actual openings.
Where the opportunities sit
- Innovative Medicine: research and clinical development, regulatory affairs, medical affairs, manufacturing and supply chain for medicines and cell therapies.
- MedTech: device engineering, surgical robotics, quality and regulatory, field service and clinical support.
- Corporate and enabling functions: finance, IT, communications, HR and legal that support both segments.
Hiring programs to look for
Large healthcare employers typically run early-career and development routes: internships and co-ops, graduate and rotational programs, and experienced-hire tracks. The page confirms hiring programs exist but does not name them, so verify the current list on the official site.
A practical next step
Decide which side of the business fits your skills—lab and clinical work versus engineering and device support—then filter openings by that segment and location. If you are early-career, look specifically for internship and rotational listings, since those often have separate application windows.
For comparison, other healthcare employers publish similar career structures, for example Pfizer and Medtronic; reading two or three side by side helps you judge which program type and business area suit you before applying.
NS1
Akamai
User reviews (0)